Tag Archive for: Vaccines

Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer

Revolutionary ‘off-the-shelf’ cancer vaccine designed to prevent the recurrence of oesophageal cancer ITOP1 to enter first-in-human Phase I/IIa clinical development in the VISTA study in H1 2025 Multicentre study to be conducted at four university cancer centres, aiming to raise the standard of care by reducing the recurrence of metastases and cancer-related deaths Oxford, UK […]

Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans

Vicebio enters the second stage of its Phase 1 Clinical Study of its lead candidate VXB-241  The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025 Moncef Slaoui, former Chief Scientific Advisor of Operation Warp Speed & former […]

Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine

Financing led by new investor TCGX, alongside Goldman Sachs Alternatives, Avoro Ventures, and venBio Funding will support and accelerate development of next-generation multivalent respiratory virus vaccines using proprietary Molecular Clamp technology Commenced Phase I clinical study of bivalent vaccine targeting both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) London, UK, 23 September 2024: Vicebio […]

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors. Dr. Collins is an industry veteran with significant experience in oncology/hematology drug development and will […]

eTheRNA Announces Research Agreement with Merck to access mRNA technologies

eTheRNA immunotherapies NV (“eTheRNA”) is pleased to announce the start of a strategic partnership with Merck with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA’s proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck. The ongoing pandemic has underlined the capability for mRNA vaccines as […]